Acquisitive Icon is at it again as it snaps up a majority stake in British site network company MeDiNova Research with an option to buy out the remaining shares penned into the deal.
Coventry, England-based MeDiNova Research, a network with research sites in key markets in Europe and Africa, will help Icon boost its geographic footprint and its patient recruitment capabilities while complementing its existing site network in the U.S., known as PMG Research, which it bought back in 2015.
Founded in 2000, MeDiNova is a network of 33 active clinical research sites in the U.K., Spain, South Africa, Poland and Romania. It works across musculoskeletal, respiratory, cardiovascular, dermatology, infectious disease, metabolic, general health and vaccine studies with about 160 employees. It focuses on phases 2 to 4 (postmarketing) studies.
Kumar Muthalagappan, CEO at MeDiNova Research, said: “Icon provides MeDiNova with a great opportunity for continued growth through scaling our knowledge, infrastructures and healthcare relationships. The MeDiNova-Icon combination will further enhance our highly productive models to deliver best in class site performance for the industry.”
Dr. Steve Cutler, CEO at Icon, added: “A successful element of our strategy has been our integrated PMG site network in the U.S. and our ability to grow alliances with third party sites and healthcare institutions in the U.S. and Europe. MeDiNova provides us with a platform to further expand our site network in key EMEA markets and will help us to recruit patients into studies faster. MeDiNova’s experience in operating multiple site models and their strong therapeutic expertise will greatly benefit our customers’ development programmes.”
By Ben Adams
Source: Fierce Biotech
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
